The entire annual ceremony is divided into two parts: the annual work conference and the grand banquet.

Huang Bisheng, Chairman of Tianhao Group, delivered a welcome speech

Full life cycle health management platform of "pre diagnosis, treatment, rehabilitation, and care"

As a highly socially responsible company, Tianyuan Biotechnology always adheres to its corporate culture. Chairman Huang Bisheng, the leader of Tianhao Group, shared the vision and responsibility of establishing Zhejiang Tianyuan Biotechnology Co., Ltd. on site.

With the release of the "Healthy China 2030" plan by the State Council, the biopharmaceutical health industry has become a new development direction for Tianhao Holdings. On the basis of establishing Zhejiang Tianyuan Biotechnology Co., Ltd., the group has jointly established the "Immune Monitoring Joint Laboratory" with the National Health Commission's research institute and the Biomedical Innovation Research Institute with Ningbo University, actively implementing the strategy of "co construction and sharing, national health" proposed in the Outline. At the same time, relying on relevant policies at the provincial and municipal levels, we will integrate our own industrial sectors in the outline of "Future Communities - Future Health Scenarios", strive to build a "pre diagnosis, treatment, and health care" full life cycle health management system, and achieve precise treatment with "maximum health benefits with the least amount of money".

After 20 years of cultural and heritage accumulation, we are now standing at a new starting point for the comprehensive upgrading of the industry and the diversified development of the company. Faced with the opportunities and challenges brought by the rapid development of artificial intelligence and biopharmaceutical industries, in the next 20 years, Tianhao Holdings will continue to closely follow the direction of national strategy and provincial and municipal policy formulation, grasp the new trends in industry development, further cooperate with the National Health Commission Research Institute, Ningbo University, and other institutions at a deeper level, and seek new breakthroughs in enterprise development. Focus on building a large consulting industry pattern; Optimize the structural allocation of the new energy industry; Building a new industrial module based on digital information, integrating biopharmaceutical resources and cellular gene technology, further consolidating the strategic pattern of group oriented and diversified development.

Chairman Huang Bisheng of Tianhao Group's Tianyuan Biotechnology showcased to us the entrepreneurial spirit of "revitalizing the national spirit and achieving industrial service to the country".

The profound significance of strategic cooperation between research institutes of the National Health Commission

Health is an important symbol of national prosperity and strength, and it is also the common pursuit of the broad masses of the people. Since the 20th National Congress of the Communist Party of China, the Party Central Committee has insisted on placing the protection of people's health in a strategic position of priority development. After proposing the implementation of the Healthy China strategy at the 19th National Congress of the Party, it once again emphasized in the report of the 20th National Congress of the Party that promoting the construction of a Healthy China, placing health in a strategic position of priority development, and making health a major livelihood project and placing it on the important agenda.

To this end, according to the requirements of the Party Central Committee and the State Council to promote the construction of a healthy China, the National Health Commission Research Institute for Grassroots Health Treatment Innovation and Development Research Center, together with experts from several authoritative medical research institutions and innovative enterprise consortia, jointly set up and launched the future community health demonstration project to build Internet plus+medical care+security for grass-roots medical institutions, and promote the in-depth integration of culture, education and sports. This program is organized and implemented through the collaborative innovation and cooperation model of production, learning, research, and use. Under the joint promotion of the national policy guidance, the deep excavation of patients' real needs, and the situation of industry development and change, it will deeply promote the change of regional grass-roots patients' medical care model, greatly improve patients' medical experience, and provide health protection for grass-roots communities. Provide digital medical support, Enhance the level of community protection.

On December 8, 2020, Zhejiang Tianyuan Biotechnology Co., Ltd., together with the National Health Commission Research Institute and Zhejiang University, launched the Future Community Active Health Demonstration Project, which is the first pilot of community immunization protection in China. The two sides jointly built the first metabolic immunization monitoring joint laboratory in China, drafted the first immunization evaluation standards and evaluation models in China, and jointly built the first community active health immunization demonstration in China. In July 2023, they obtained the first five-star experimental qualification and certificate that meets the standard operation in China.

In 2024, the strategic cooperation with the Science and Technology Research Institute of the National Health Commission will be upgraded on the existing basis, launching a nationwide network to achieve online and offline interactive digital health solutions. With innovative work, more innovations and ideas will be provided to achieve the construction of a healthy China, laying a solid foundation for the subsequent work. Three years of national anti epidemic experience have proved that the importance of proactive health protection at the community level is very prominent. Individuals should pay attention to immune maintenance and improve immunity. National departments will work together with various sectors of society to provide and support immune products, technologies, and services, and make every effort to enhance the immunity and protection awareness of the general public.

Specialized technology to expand the market

During the work meeting, General Manager Zhu Pengcheng of Tianhao Group Tianyuan Biotechnology Co., Ltd. comprehensively introduced the projects related to immune testing, gene testing, and stem cell storage that will be carried out in 2023. 2024 is a year of steady development for Tianyuan. We will focus on building a marketing system, team, and a comprehensive online marketing and promotion platform, expanding market investment, and improving product systems.